HMHadija Mwamtemi

Hadija Mwamtemi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hadija Mwamtemi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas

    by Clara Chamba, Heavenlight Christopher, Emmanuel Josephat, Julius Sseruyange, Alisen Ayitewala, Kieran Howard, Helene Dreau, Adam Burns, Ismail Legason, Isaac Otim, et al.

    Burkitt’s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers ( MYC mutations, MYC –immunoglobulin translocations and Epstein–Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation ( n = 212). The best-performing model was externally validated in a prospective real-world cohort ( n = 56). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901–0.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942–1.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8 d to 6.5 d ( P = 4.42 × 10 −10 ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV + BL and may substantially reduce treatment delays in resource-limited settings.


  • Open Access

    Rituximab for children with EBV-positive Burkitt lymphoma in East Africa

    by William Frank Mawalla, Caroline Achola, Hadijah Nabalende, Isaac Otim, Ismail D. Legason, Martin D. Ogwang, Pamella M. Aol, Godlove Sandi, Hadija Mwamtemi, Salama Mahawi, et al.

    The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)–positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged ≤25 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)–based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade ≥3 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.